284 related articles for article (PubMed ID: 12601144)
1. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
Marijt WA; Heemskerk MH; Kloosterboer FM; Goulmy E; Kester MG; van der Hoorn MA; van Luxemburg-Heys SA; Hoogeboom M; Mutis T; Drijfhout JW; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2742-7. PubMed ID: 12601144
[TBL] [Abstract][Full Text] [Related]
2. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
[TBL] [Abstract][Full Text] [Related]
3. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
4. Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission.
van der Torren CR; van Hensbergen Y; Luther S; Aghai Z; Rychnavská ZS; Slot M; Scherjon S; Kröger N; Ganser A; Weissinger EM; Goulmy E; Hambach L
PLoS One; 2015; 10(3):e0119595. PubMed ID: 25774796
[TBL] [Abstract][Full Text] [Related]
5. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
7. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.
Kircher B; Stevanovic S; Urbanek M; Mitterschiffthaler A; Rammensee HG; Grünewald K; Gastl G; Nachbaur D
Br J Haematol; 2002 Jun; 117(4):935-9. PubMed ID: 12060133
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion.
Kircher B; Wolf M; Stevanovic S; Rammensee HG; Grubeck-Loebenstein B; Gastl G; Nachbaur D
J Immunother; 2004; 27(2):156-60. PubMed ID: 14770087
[TBL] [Abstract][Full Text] [Related]
10. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.
Mutis T; Blokland E; Kester M; Schrama E; Goulmy E
Blood; 2002 Jul; 100(2):547-52. PubMed ID: 12091347
[TBL] [Abstract][Full Text] [Related]
11. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
12. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
13. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
14. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.
Gillespie G; Mutis T; Schrama E; Kamp J; Esendam B; Falkenburg JF; Goulmy E; Moss P
Hematol J; 2000; 1(6):403-10. PubMed ID: 11920221
[TBL] [Abstract][Full Text] [Related]
15. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
16. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
17. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
[TBL] [Abstract][Full Text] [Related]
19. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
Dickinson AM; Wang XN; Sviland L; Vyth-Dreese FA; Jackson GH; Schumacher TN; Haanen JB; Mutis T; Goulmy E
Nat Med; 2002 Apr; 8(4):410-4. PubMed ID: 11927949
[TBL] [Abstract][Full Text] [Related]
20. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
